News

On World Sight Day, leading experts in ophthalmology look at artificial intelligence and how it could impact diagnosing and finding diseases in the future.

According to the company, MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.

The Eye Care Network adds a longstanding, CME-certified to its live event programming.

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics

According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the development of Practice Insights for clinicians.

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months.

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

The effort represents a consortium of researchers from Penn Medicine, Penn Engineering, the University of Michigan Kellogg Eye Center, St. John Eye Hospital in Jerusalem, and Gyeongsang National University College of Medicine in Korea.

According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC Inc. It also has secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing.

A team of researchers at Arizona State University has developed tools to aid in the diagnosis of myopic maculopathy.

Changes associated with Alzheimer's disease extend beyond the brain.

Lotfi Merabet, OD, PhD, MPH, discusses his role as co-chairman of a National Eye Institute initiative focused on advancing research in cerebral visual impairment (CVI). The initiative's key goals include raising awareness about CVI, establishing clear diagnostic criteria, and developing a national registry to track patients and their conditions over time. CVI, a complex condition that affects how the brain processes visual information, requires a multidisciplinary approach involving not only ophthalmologists and optometrists but also neuroscientists, educators, and rehabilitation specialists.

Coordinated by the International Agency for the Prevention of Blindness under the Love Your Eyes campaign banner, World Sight Day 2024 is putting children front and center in this year’s campaign.

Jeff Todd, president and CEO of Prevent Blindness, and Donna Fishman, Director of the National Center for Children’s Vision and Eye Health at Prevent Blindness, join David Hutton of Ophthalmology Times to discuss the report.

The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities.

The donation will support the development of the Artificial Intelligence Innovation Center, a collaborative hub with a focus of preserving the vision of patients with various eye conditions and eliminating blindness.

The resubmission comes after receiving a Complete Response Letter at the end of 2023.

Marketed as Triesence, it is a preservative free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

The award from the National Institutes of Health will enable a team of researchers to investigate Alzheimer and Parkinson progression through the eye.

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.

Because the inner retinal function is thought to affect the emmetropization process, authors suggested that caffeine may be involved in ocular growth

The company’s flagship product is Reti-CVD, an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using a retina scan.

The TECNIS Odyssey IOL is a new full vision range IOL built on the TECNIS platform.

Clobetasol is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery.

Published data from a pair of Phase 3 clinical trials demonstrated a reversal of pharmacologically-induced mydriasis with a favorable safety profile.